Bibliography
- Workshop on Natural History Studies of Rare Diseases: meeting the Needs of Drug Development and Research. 2012. Accessed from https://events-support.com/Documents/Summary-NHS.pdf
- Rare diseases: challenges and opportunities for social entrepreneurs. Sireau N. edited Greenleaf, 2013. Accessed from http://www.amazon.co.uk/Rare-Diseases-Challenges-Opportunities-Entrepreneurs/dp/1906093520/ref=sr_1_1?ie=UTF8&qid=1367920851&sr=8-1&keywords=rare+diseases
- CPMP (Committee for Proprietary Medicinal Products) Points to Consider on Application With 1. Meta-Analyses; 2. One Pivotal Study (CPMP/EWP/2330/99; London: CPMP)
- Sasinowski FJ. Quantum of effectiveness evidence in FDA's approval of orphan drugs cataloguing FDA's flexibility in regulating therapies for persons with rare disorders. National Organization for Rare Disorders; Danbury, CT: 2011
- EMA/882900/2011. Assessment Report Glybera (Alipogene tiparvovec)
- Heemstra HE, Leufkens HG, Rodgers RP, et al. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Drug Discov Today 2011;16(1–2):73-80
- Pariser AR, Slack DJ, Bauer LJ, et al. Characteristics of rare disease marketing applications associated with FDA product approvals 2006–2010. Drug Discov Today 2012;17(15–16):898-904
- ICH Harmonised Tripartite Guideline. General Considerations for Clinical Trials E8. 1997
- CHMP/EWP/83561/2005. CHMP Guideline on Clinical Trials in Small Populations
- 21 CFR 314.510